Zenith Drugs manufactures and sells a variety of pharmaceutical formulations including oral liquids, powders, and ointments to government agencies and private pharmaceutical companies in India and emerging international markets.
The company lacks a durable moat as evidenced by low net margins of 4.4% and a significant decline in EPS despite revenue growth, indicating a lack of pricing power in the generic drug market. While they claim a cost advantage, the negative cash conversion and reliance on low-margin government tenders suggest they are a price-taker in a commoditized industry.
Management has prioritized aggressive capacity expansion, specifically into tablet manufacturing, which has led to a sharp increase in depreciation and interest costs. This reinvestment has yet to translate into improved bottom-line results, as evidenced by the negative cash conversion and declining profitability metrics.
The business collapsed as the aggressive capacity expansion into tablets failed to generate incremental margins, instead drowning the company in fixed depreciation and interest costs. The negative cash conversion cycle eventually triggered a liquidity crisis, exacerbated by the fact that reported cash balances were never reconciled with bank statements. As the promoter-linked transactions with Biogenesis Corp drained remaining value, the lack of internal controls and regulatory penalties finally led to a total loss of investor confidence and a delisting event.
RichFakir rates Zenith Drugs Ltd's business quality as mediocre — 40/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Zenith Drugs Ltd is trading about 9% above our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Zenith Drugs Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Zenith Drugs Ltd's fair value is about ₹33 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →